Paper Provides Insights into How CROs Are Employing Science
 and Technology Innovations to Transform Clinical Development Programs

Raleigh, NC, Feb. 7, 2012 - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a trusted process for delivering reliable results, today announced it has released a new white paper titled, "The Innovation Imperative: How CROs Are Driving The Transformation of Clinical Research." INC Research's paper takes a critical look at the most significant innovations in science and technology and how CROs are implementing these advancements to transform the overall clinical development process.

"The drug development industry is experiencing a new wave of R&D innovation, primarily as a response to financial pressures," said INC Research CEO James Ogle. "CROs are in a position to not only take costs out of the clinical development process, but also to spawn new approaches and techniques to the process itself. As a result, modern alliance partnership models will help bring better and safer drugs to market more efficiently."

The recent shift in the biopharmaceutical company-CRO relationship from project-specific outsourcing to strategic alliances has created an environment in which biopharms are considering CROs innovation partners. Based on furthering portfolio objectives, these multi-year alliances are based on higher levels of engagement with the CRO and leverage years of perspective, expertise and tactical approaches. INC Research's white paper highlights how partnership models are evolving and explores the ways CROs are transforming the practice of clinical trials by applying digital and scientific innovations, including better study designs for more efficient endpoints and next-generation data management and patient recruitment strategies to accelerate new drug development.

INC Research is at the forefront of innovating all stages of the clinical trial process, from initial first-in-human clinical trial designs to Phase IV trials.  Working with INC Research, customers access innovations that bring new life to existing clinical development programs and accelerate new ones, helping them to achieve their biggest R&D ambitions.

To download a copy of "The Innovation Imperative: How CROs Are Driving The Transformation of Clinical Research," visit www.incresearch.com/transform. For more information on INC Research's clinical development capabilities and comprehensive clinical and consulting services, click here.
  
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The Company's Trusted Process^® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
  

CONTACT:

Lori Dorer, Media, (513) 345-1685